designtx.com (DSGN) - חוב להון עצמי

Design Therapeutics (DSGN) management aims to correct genetic malfunctions by regulating gene function, guided by strict ethical principles. The brand is highly regarded in medicine for developing molecules to treat complex neurological pathologies. Current developments in the field of hereditary diseases confirm the firm's technological growth. The market trend on GURU.Markets shows that the total debt-to-equity ratio is 0.01.

Design Therapeutics focuses on high-risk GeneTAC developments for the treatment of neurodegeneration. By analyzing the company's leverage history, an investor assesses the proportion of debt to equity. This metric measures the balance sheet structure's dependence on external financing and its sensitivity to borrowing costs. Low debt levels currently offset the absence of a commercial product, ensuring the financial sustainability of R&D until clinical trials are completed.